Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06629428 · ClinicalTrials.gov registry record · Early Phase 1

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

A Early Phase 1 study of Multiple Sclerosis (MS) - Relapsing-remitting, sponsored by Georgia State University.

Recruiting
Registry status
Early Phase 1
Development phase
25
Enrollment target
2
Study locations

NCT06629428 is a Early Phase 1 study of Multiple Sclerosis (MS) - Relapsing-remitting that is actively recruiting participants, run by Georgia State University. The registered enrollment target is 25 participants, below the 100-participant average among 5 other Multiple Sclerosis (MS) - Relapsing-remitting trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06629428, a Early Phase 1 study of Multiple Sclerosis (MS) - Relapsing-remitting, is actively recruiting participants, sponsored by Georgia State University.

RECRUITING
Registry status
Early Phase 1
Development phase
25 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function, disability status, and cognition will be assessed. Additionally, they will experience large-scale slip perturbations on a treadmill under the protection of a safety harness at the last assessment. The outcome measures will be compared across the assessments to examine the effects of ublituximab on improving their walking function, disability status, cognition, and the responses to the unexpected slip perturbation.

Conditions Studied

Multiple Sclerosis (MS) - Relapsing-remitting

Interventions

  • DRUG Ublituximab

Study Locations (2)

Georgia

  • Georgia State University - Atlanta
  • Atlanta Neuroscience Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2025-11-13
Est. Completion 2026-12-31
Phase Early Phase 1

Sponsor

Georgia State University

45 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06629428

The ClinicalTrials.gov registry entry for NCT06629428 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 5 other Multiple Sclerosis (MS) - Relapsing-remitting trials with a reported enrollment target (75% lower). The listed sponsor is Georgia State University, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis (MS) - Relapsing-remitting appearing as the primary indexed condition, and to 1 intervention - of which Ublituximab is the first listed.

NCT06629428 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT06629428 about?

NCT06629428 is a clinical study titled "Effects of Ublituximab on Motor Functions in Multiple Sclerosis". The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function...

What is the current status of trial NCT06629428?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2025-11-13. Estimated completion is 2026-12-31.

What conditions does trial NCT06629428 study?

This clinical trial studies the following conditions: Multiple Sclerosis (MS) - Relapsing-remitting.

What interventions are being tested in trial NCT06629428?

The interventions under investigation include: Ublituximab (DRUG).

Who is sponsoring clinical trial NCT06629428?

This trial is sponsored by Georgia State University, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06629428 being conducted?

This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis (MS) - Relapsing-remitting

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis (MS) - Relapsing-remitting

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.